Featured Publications
PI3Kγ in B cells promotes antibody responses and generation of antibody-secreting cells
Lanahan S, Yang L, Jones K, Qi Z, Cabrera E, Cominsky L, Ramaswamy A, Barmada A, Gabernet G, Uthaya Kumar D, Xu L, Shan P, Wymann M, Kleinstein S, Rao V, Mustillo P, Romberg N, Abraham R, Lucas C. PI3Kγ in B cells promotes antibody responses and generation of antibody-secreting cells. Nature Immunology 2024, 25: 1422-1431. PMID: 38961274, DOI: 10.1038/s41590-024-01890-1.Peer-Reviewed Original ResearchAntibody-secreting cellsMemory B cellsB cellsKinase activity-dependent mannerDifferentiation of antibody-secreting cellsAntibody responseGeneration of antibody-secreting cellsInborn errors of immunityActivity-dependent mannerMouse immunization modelFate choiceT cell-dependent antigensToll-like receptor activationTranscriptional programsB cell biologyPhosphoinositide 3-kinase-gammaErrors of immunityNaive B cellsTransduce signalsActivated B cellsB lineage cellsRobust antibody responsesHumoral defectsHumoral immunityReceptor activation
2017
Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib
Rao VK, Webster S, Dalm VASH, Šedivá A, van Hagen PM, Holland S, Rosenzweig SD, Christ AD, Sloth B, Cabanski M, Joshi AD, de Buck S, Doucet J, Guerini D, Kalis C, Pylvaenaeinen I, Soldermann N, Kashyap A, Uzel G, Lenardo MJ, Patel DD, Lucas CL, Burkhart C. Effective “activated PI3Kδ syndrome”–targeted therapy with the PI3Kδ inhibitor leniolisib. Blood 2017, 130: 2307-2316. PMID: 28972011, PMCID: PMC5701526, DOI: 10.1182/blood-2017-08-801191.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsChemokinesChildChild, PreschoolClass I Phosphatidylinositol 3-KinasesDemographyDose-Response Relationship, DrugFemaleHumansImmunoglobulin MImmunologic Deficiency SyndromesInfantLymph NodesLymphocyte ActivationMaleMolecular Targeted TherapyMutationOrgan SizePhenotypePrimary Immunodeficiency DiseasesProtein Kinase InhibitorsPyridinesPyrimidinesRatsSpleenT-LymphocytesTOR Serine-Threonine KinasesTransfectionConceptsImmune dysregulationT cellsB cellsElevated serum immunoglobulin MPI3K/Akt pathway activityDose-escalation studyLymph node sizeSenescent T cellsWeeks of treatmentDose-dependent suppressionTransitional B cellsTumor necrosis factorDose-dependent reductionPrecision medicine therapiesSerum immunoglobulin MNaive B cellsT cell blastsAkt pathway activityAPDS patientsPI3Kδ pathwayInflammatory markersPD-1Clinical parametersSpleen volumeImmune deficiency